SOAN - AngioSoma, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD

AngioSoma, Inc.

2500 Wilcrest Drive
3rd Floor Suite 300
Houston, TX 77042
United States

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Ms. Alex K. BlankenshipCEO, Pres, Sec., Treasurer, Principal Exec. Ofc., Principal Fin. & Acc. Ofc. and Director50.5kN/A1963
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


AngioSoma, Inc. operates as a clinical stage biotechnology company. The company's lead drug candidates include Liprostin that completed Phase I and three Phase II clinical trials, and Prostaglandin E1 that completed Phase II clinical trials for the treatment of peripheral artery diseases. It also markets a line of nutraceutical supplements under the SomaCeuticals name. AngioSoma, Inc. was founded in 2016 and is based in Houston, Texas.

Corporate Governance

AngioSoma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.